For instance, the glucose transporter type 1 (GLUT1) inhibitor WZB117 blocks glucose entry into cancer cells, disrupting glycolysis, reducing intracellular ATP and glycolytic enzymes, ultimately causing cell cycle arrest, senescence, and necrosis (3, 34). This evidence concerns the gene SLC2A1 and cancer.